Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
1. A method of treating a pulmonary disease or disorder that is not a cancer in a lung of a subject in need thereof, the method comprising
applying to the subject a course of therapy of a compound that constitutes a means for selectively inhibiting Bcl-2 or Bcl-xL in a pharmaceutical composition,
wherein the pharmaceutical composition is formulated such that the compound contacts p16 positive senescent cells located in or around the lung that are promoting symptoms of the pulmonary disease or disorder, thereby selectively eliminating such cells and relieving such symptoms;
wherein the course of therapy includes:
(1) a treatment period during which the compound is administered through a pulmonary airway into the lung of the subject in a manner such that the compound selectively removes senescent cells from the lung, wherein the senescent cells are defined as p16 positive cells that are not cancer cells; followed by
(2) a therapeutic period of at least two weeks, during which the compound is not administered, and the symptoms of the pulmonary disease or disorder in the lung are relieved as a result of administration of the compound to the lung during the treatment period.
2. The method of claim 1 , wherein the means for selectively inhibiting Bcl-2 or Bcl-xL is ABT-263 (Navitoclax), or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the means for selectively inhibiting Bcl-2 or Bcl-xL is selected from WEHI-539, A-1155463, ABT-737, ABT-199, Obatoclax, BXI-61, BXI-72, 2,3-DCPE, “Compound 21” (R)-4-(4-chlorophenyl)-3-(3-(4-(4-(44(4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenylsulfonamido)phenyl)piperazin-1-yl)phenyl)-5-ethyl-1-methyl-1H-pyrrole-2-carboxylic acid, “Compound 14” (R)-5-(4-Chlorophenyl)-4-(3-(4-(4-(4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenylsulfonamido)phenyl)piperazin-1-yl)phenyl)-1-ethyl-2-methyl-1H-pyrrole-3-carboxylic acid, “Compound 15” (R)-5-(4-Chlorophenyl)-4-(3-(4-(4-(4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenylsulfonamido)phenyl)piperazin-1-yl)phenyl)-1-isopropyl-2-methyl-1H-pyrrole-3-carboxylic acid, BM-957, BM-1074, BM-1197, and pharmaceutically acceptable salts thereof.
4. The method of claim 1 , wherein the pulmonary disease or disorder is idiopathic pulmonary fibrosis (IPF).
5. The method of claim 1 , wherein the pulmonary disease or disorder is chronic obstructive pulmonary disease (COPD).
6. The method of claim 1 , wherein the pulmonary disease or disorder has been caused or exacerbated by smoking.
7. The method of claim 1 , wherein the compound is administered in a sustained-release formulation.
8. The method of claim 1 , wherein the compound is administered as an aerosol formulation.
9. The method of claim 1 , wherein the compound is administered by inhalation.
10. The method of claim 1 , wherein the compound is administered intratracheally or by intubation.
11. The method of claim 1 , which has the effect of reducing the amount of fibrotic pulmonary tissue in the lung.
12. The method of claim 1 , which has the effect of increasing the average peripheral capillary oxygen saturation (SpO 2 ) in the subject.
13. The method of claim 1 , wherein a single dose of the compound is administered to the subject during the treatment period.
14. The method of claim 1 , wherein the therapeutic period lasts at least two months.
15. A method of selectively removing senescent cells from a lung of subject in need thereof, the method comprising:
(1) contacting senescent cells in the lung of the subject with the senolytic compound by administering the compound in an effective pharmaceutical formulation through a pulmonary airway into the lung, thereby selectively promoting apoptosis of such cells; and then
(2) waiting for a period of at least one month before administering more of the senolytic compound to the lung;
wherein the senolytic compound is a means for selectively inhibiting Bcl-2 or Bcl-xL; and
wherein the senescent cells are defined as p16 positive cells that are not cancer cells.
16. The method of claim 15 , wherein the means for selectively inhibiting Bcl-2 or Bcl-xL is ABT-263 (Navitoclax), or a pharmaceutically acceptable salt thereof.
17. The method of claim 15 , wherein the means for selectively inhibiting Bcl-2 or Bcl-xL is selected from WEHI-539, A-1155463, ABT-737, ABT-199, Obatoclax, BXI-61, BXI-72, 2,3-DCPE, “Compound 21” (R)-4-(4-chlorophenyl)-3-(3-(4-(4-(44(4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenylsulfonamido)phenyl)piperazin-1-yl)phenyl)-5-ethyl-1-methyl-1H-pyrrole-2-carboxylic acid, “Compound 14” (R)-5-(4-Chlorophenyl)-4-(3-(4-(4-(4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenylsulfonamido)phenyl)piperazin-1-yl)phenyl)-1-ethyl-2-methyl-1H-pyrrole-3-carboxylic acid, “Compound 15” (R)-5-(4-Chlorophenyl)-4-(3-(4-(4-(4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenylsulfonamido)phenyl)piperazin-1-yl)phenyl)-1-isopropyl-2-methyl-1H-pyrrole-3-carboxylic acid, BM-957, BM-1074, BM-1197, and pharmaceutically acceptable salts thereof.